Keeps Biopharma KRX:256940KOSDAQ
킵스파마 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked8since Sep 11
In Q2 2026, Keeps Biopharma reported revenue of ₩74.9bn, up 72.8% year on year, and an operating loss of ₩2.4bn. Keeps Biopharma (킵스파마) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Revenue +30% Insider buying Clinical trial filing Share pledge Screener
Keeps Biopharma quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩74.9bn | +72.8% | −₩2.4bn margin −3.2% | −₩9.0bn |
| Q1 2026 | ₩59.4bn | +46.2% | −₩664m margin −1.1% | ₩5.7bn |
| Q4 2025 derived | ₩45.2bn | +37.7% | ₩1.0bn margin 2.2% | −₩9.2bn |
| Q3 2025 | ₩40.9bn | +29.8% | ₩1.4bn margin 3.5% | −₩446m |
| Q2 2025 | ₩43.3bn | +37.6% | −₩976m margin −2.3% | ₩718m |
| Q1 2025 | ₩40.6bn | +28.2% | ₩89m margin 0.2% | −₩1.4bn |
| Q4 2024 derived | ₩32.8bn | +5.9% | −₩1.3bn margin −4.0% | ₩1.4bn |
| Q3 2024 | ₩31.5bn | +29.8% | ₩1.0bn margin 3.2% | −₩1.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Keeps Biopharma top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Keeps Biopharma news Korean headlines
-
킵스파마 자회사, 유럽당뇨병학회서 경구 플랫폼 작용기전 확인…“속효성 제형까지 확장”
1 more on this story · 1 outlets
- [더벨]킵스파마, 유럽당뇨병학회서 경구 플랫폼 작용기전 확인머니투데이 · Oct 1 16:06